On January 31, 2022, MEGIN, headquartered in Espoo, Finland, announced the sale of its fourth-generation magnetoencephalography (MEG) technology, the TRIUX™ neo, to the Norman Fixel Institute for Neurological Diseases at University of Florida Health (UF Health). The Norman Fixel Institute coordinates the efforts of clinicians, researchers, and therapists from different fields such as aging, bioengineering, communication sciences, computer science, health psychology, internal medicine, neurology, neuroscience, neurosurgery, occupational therapy, physical medicine and kinesiology, physical therapy, radiology, rehabilitation science, and speech therapy. UF Health’s patient-centric approach provides access to interdisciplinary, comprehensive care and research.
MEGIN Announces Sale of TRIUX™ neo to the Norman Fixel Institute for Neurological Diseases at University of Florida Health; Technology Is Used for Functional Brain Imaging; Immediate Application in Epilepsy and Brain Tumor Patients Planned
Login Or Register To Read Full Story